

**Александра Капедановска Несторовска, PhD.**, е доцент на Фармацевтскиот факултет при Универзитетот “Св. Кирил и Методиј” во Скопје. Магистирала и докторирала на Фармацевтскиот факултет - Скопје во областа на клиничка фармација и фармакогенетика на проблематика која се однесува на молекуларна карактеризација на спорадичен колоректален карцином, фармакогенетски водена индивидуализација на терапија и фармакоекономска евалуација на фармакогенетските тестови (“Влијание на нископенетрабилните гени за развој на колоректален карцином кај пациенти од Република Македонија-Магистерски труд, 2009; Влијание на лек - метаболитичките гени за индивидуализација на терапијата- Докторска дисертација- 2015). Таа е специјалист по клиничка фармација (“Клинички студии во педијатриска популација- регулаторни и етички аспекти”- здравствената специјализација од областа Клиничка фармација, 2011). Здравствената специјализација од областа Аптекарска пракса ја завршила во 2018 год.

Нејзино поле на научен и наставен интерес се клиничка фармација, фармацевтска грижа, фармакоекономија, фармацевтска хемија.

Од 2004 е научен соработник во два апликативни центри при Фармацевтскиот факултет во Скопје (Националниот Фармакоинформативен центар и Центарот за биомолекуларни фармацевтски анализи) и активно придонесува во нивниот развој како високо професионален и стручен информативен сервис на здравствените работници од примарната, секундарната и терцијерната здравствена заштита и во унапредувањето на научно истражувачката дејност и практичната примена на молекуларната дијагностика и фармакогенетика во нашата земја.

Во 2013 е избрана и сеуште го реализира професионалниот ангажман како координатор на Секцијата за Клиничка фармација при Македонското Фармацевтско Друштво.

Учесник е во голем број меѓународни и национални проекти од кои како по значајни реализирани во последните 5 години се издвојуваат следните: Биолошки слични лекови- регулаторни и клинички предизвици за нивна употреба ( 2015)

Фармакоекономска анализа: Трошок-Ефикасност за лекот Pertuzumab (pertuzumab) кај пациенти со HER 2 позитивен метастатски карцином на дојка и неoadјувантен третман кај пациенти со локално напреднат, инфламаторен или ран стадиум на HER 2 позитивен карцином на дојка во Р.Македонија (2016-2017); Прифаќање и адаптирање на здравствена технологија за лекот Gazyva (Obinutuzumab) во праволиниски третман на пациенти со хронична лимфоцитна леукемија (ХЛЛ) во Република Македонија (2016-2017); Анализа на минимизација на трошок за споредба на употреба на субкутана наспроти интравенска форма на апликација на Herceptin.

(2014-2015); Анализа на минимизација на трошок за споредба на употреба на субкутана наспроти интравенска форма на апликација на Herceptin (trastuzumab) во третман на карцином на дојка ( 2014-2015). Анализа на минимизација на трошок за споредба на употреба на субкутана наспроти интравенска форма на апликација на Mabtera (rituximab) во третман на хронична лимфатична леукемија ( 2015-2016).

Во 2007 година, како дел од активностите во рамките на меѓународниот проект “Реконструкција на фармацевтската едукација во Република Македонија (2004-2007)”, остварил студиски престој на Катедра за биохемија и биофизика, Универзитет на Стокхолм, Стокхолм, Шведска.

Стручно-апликативната дејност вклучува учество во работата на комисиите на Агенцијата за лекови и медицински средства на РМ како (комисија за одобрување на увоз на лекови кои немаат одобрение за ставање во промет; стручна проценка на безбедностпри употреба на лековите; Комисија за оценување на условите за добра клиничка пракса).

Таа е активен член на Македонско фармацевтско друштво и Фармацевската комора на Република Македонија и член на Македонско здружение за хумана генетика, Македонско здружение за биохемија и молекуларна биологија, Македонско здружение на болнички фармацевти, Европско здружение на клинички фармацевти и Европско здружение за хумана генетика / European Society of Human genetics- ESHG

Автор и ко-автор е на голем број оригинални научни трудови објавени во домашни и странски научни списанија. ([Листа на публикации- ЛИНК](#)).

2019-2014

1. A. Kapedanovska Nestorovska, K. Jakjovski, Z. Naumovska, Z. Sterjev, N. Matevska Geskovska, K. Mladenovska, Lj. Suturkova and A. Dimovski; AKR1D1\*36 C>T (rs1872930) allelic variant is associated with variability of the CYP2C9 genotype predicted pharmacokinetics of ibuprofen enantiomers – a pilot study in healthy volunteers; *Acta Pharm.* **69** (2019) xx–xx <https://doi.org/10.2478/acph-2019-0032>.
2. Aleksandra Kapedanovska Nestorovska, Zorica Naumovska, Krume Jakovski, Zoran Sterjev, Nadica Matevska Geskovska, Aleksandar Dimovski, Ljubica Suturkova. Allele frequency and genotype distribution of aldo keto reductase 1D1 (AKR1D1) rs1872930 genetic variant in a Macedonian population. *Macedonian Pharmaceutical Buliten*, 64(1).
3. A. Kapedanovska Nestorovska, Z. Sterjev, Z. Naumovska, A. Dimovski, A. Grozdanova, L. Suturkova, Cost –effectiveness analysis of pertuzumab as first line neoadjuvant treatment option for patients her2 + breast cancer in republic of macedonia.. *Value in Health* , Volume 21 , S29..
4. Selvete Shuleta-Qehaja, Aleksandra Kapedanovska Nestorovska, Zorica Naumovska, Petar Stefanovski, Aleksandar J Dimovski, Zoran Sterjev, Ljubica Shuturkova. *CYP2D6 polymorphisms and the therapeutic outcome with Tamoxifen therapy in breast cancer patients from Kosovo*. *Macedonian Pharmaceutical Buliten*, 64(2).
5. Qerimi V, Nestorovska AK, Sterjev Z, Genadieva-Stavric S, Suturkova Lj.; Cost-effectiveness analysis of treating transplant-eligible multiple myeloma patients in Macedonia. *Clinicoecon Outcomes Res.* 2018 Jun 20;10:327-338. doi: 10.2147/CEOR.S152437.
6. Matevska-Geshkovska N, Staninova-Stojovska M, Kapedanovska-Nestorovska A, Petrushevsk-Angelovska N, Panovski M, Grozdanovska B, Mitreski N, Dimovski A. Influence of MSI and 18q LOH markers on capecitabine adjuvant monotherapy in colon cancer patients. *Pharmgenomics Pers Med.* 2018 Nov 1;11:193-203. doi:10.2147/PGPM.S172467.
7. Naumovska Z, Nestorovska AK, Grozdanova A, Hristova K, Dimovski A, Suturkova Lj, Sterjev Z.; Evaluation of statin utilization in the Republic of Macedonia during 2013-2016; *Clinicoecon Outcomes Res.* 2018 Jun 26;10:339-347. doi: 10.2147/CEOR.S157842. eCollection 2018.
8. Zorica Naumovska\* , Katerina Brezovska , Jasmina Tonic-Ribarska , Aleksandra Kapedanovska Nestorovska , Zoran Sterjev , Aleksandra Grozdanova , Ana Filipce , Aleksandar Dimovski, Ljubica Suturkova. Optimization of Bioanalytical LC Method for Simultaneous Determination of Risperidone And Its Active Metabolite 9-OH Risperidone in Human Plasma And Urine. *IOSR Journal Of Pharmacy* www.iosrphr.org (e)-ISSN: 2250-3013, (p)-ISSN: 2319-4219 Volume 7, Issue 12 Version. 1 (December 2017), PP. 54-64
9. Biljana Lazarova, Aleksandra Kapedanovska Nestorovska, Zoran Sterjev, Ljubica Suturkova. Evaluation of costs and outcomes associated with pharmacological thromboprophylaxis (unfractionated heparin and low molecular weight heparins) of venous thromboembolism at orthopedic ward in Clinical Hospital Stip, *Macedonian Pharmaceutical Buliten.* 63 (1).

10. Vjollca Qerimi, Aleksandra Kapedanovska Nestorovska, Zoran Sterjev, Sonja Genadieva-Stavric, Ljubica Suturkov Overview of cost-effectiveness analysis and health state utilities in multiple myeloma and estimations of health state utilities from real-world macedonian data. Macedonian Pharmaceutical Buliten, 62 (2)
11. Kapedanovska Nestorovska, A et al. Cost –Effectiveness of Obinutuzumab As Frontline Treatment For Unfit Patients With Chronic Lymphocytic Leukemia In Republic of Macedonia. Value in Health , Volume 20 , Issue 9 , A736
12. Z Naumovska, A Kapedanovska Nestorovska, A Grozdanova, L Suturkova, A Dimovski, Z Sterjev. Pharmacoeconomic Evaluation of Sorafenib As First-Line Treatment for Advanced Hepatocellular Carcinoma. Value in Health, Vol. 20, Issue 9, A736 Published in issue: October-November, 2017
13. Mladenovska K, Grapci AD, Vavlukis M, Kapedanovska A, Eftimov A, Geshkovska NM, Nebija D, Dimovski AJ. Influence of SLCO1B1 polymorphisms on atorvastatin efficacy and safety in Macedonian subjects. Pharmazie. 2017 May 1;72(5):288-295. doi:10.1801/ph.2017.6960. PubMed PMID: 29441875.
14. V Qerimi, A Kapedanovska-Nestorovska, Z Sterjev, S Genadieva-Stavric, L Suturkova Treatment in Transplant Eligible Multiple Myeloma Patients in Macedonia: Development of Cost-Effectiveness Analysis Value in Health, Vol. 20, Issue 9, A435 Published in issue: October-November, 2017
15. Zorica Naumovska, Jasmina Tonic Ribarska, Ljubica Suturkova, Nestorovska K. Aleksandra, Simonovska Crcarevska, Marija Glavas Dodov, Anastas Misev, Ljupco Pejov, Ewa Szymanska, Darryl Pickering, Karla Frudenvang, Tommy N. Johansen. (S)-EL-7 SELECTIVE COMPETITIVE ANTAGONIST FOR AMPA AND KA RECEPTOR. Drug discovery and designing & 9th Annual pharmaceutical chemical analysis congress, 2-4 October 2017, Vienna Austria. Best awarded poster presentation.
16. Zorica Naumovska, Aleksandra K. Nesterovska, Zoran Sterjev, Ana Filipce, Aleksandar Dimovski, Ljubica Suturkova, Vladimir Serafimoski. Evaluation of the role of ABCB1 gene polymorphic variants on psychiatric disorders predisposition in Macedonian population. Pril(Makedon Akad Nauk Umjet Odd Med Nauki). 2017 Dec 1;38(3):71-88. doi:10.2478/prilozi-2018-0008. PubMed PMID: 29668471.
17. Oliver Nikolov , Zoran Sterjev , Aleksandar Dimovski , Aleksandra **Kapedanovska-Nestorovska** , Zorica Naumovska , Aleksandra Grozdanova , Lidija Cevreska , Borche Georgievski, Aleksandar Stojanovic , Oliver Karanfilski , Sonja Genadieva-Stavrik , Sanja Trajkova , Aleksandra Pivkova-Veljanovska , Tatjana Sotirova , Marica Pavkovic , Slobodanka Trpkovska-Terzieva , Gazmend Amzai , Lazar Cadievski , Dusko Dukovski , Ljubica Suturkova. Cost-minimization analysis of rituximab subcutaneous formulation versus intravenous administration of rituximab for the treatment of non-hodgkin's lymphoma in the republic of macedonia.; EHA Learning Center. Nikolov O. May 18, 2017; 181247
18. **Kapedanovska Nestorovska A.** Cost-effectiveness analysis of obinutuzumab as first line treatment option for patients with chronic lymphocytic leukemia in republic of macedonia. 7TH ADRIATIC AND 5TH CROATIAN CONGRESS OF PHARMACOECONOMICS AND OUTCOMES RESEARCH. 20-23 APRIL 2017 POREČ, CROATIA
19. Sterjev, Z. , Dimovski, A. , **Kapedanovska-Nestorovska, A.** , Naumovska, Z. , Grozdanova, A. , Cevreska, L. , Georgievski, B., Stojanovic, A. , Karanfilski, O. , Genadieva-Stavrik, S. , Trajkova, S. ,Pivkova-Veljanovska, A. , Sotirova, T. , Pavkovic, M. , Trpkovska-Terzieva, S. , Amzai, G. , Cadievski, L. , Dukovski, D. , Nikolov, O. , Suturkova, Lj. COST-

MINIMIZATION ANALYSIS OF RITUXIMAB SUBCUTANEOUS INJECTION FOR NON-HODGKIN'S LYMPHOMA IN THE REPUBLIC OF MACEDONIA. 2<sup>nd</sup> congress of the Macedonian hematology association with international participation (18-20 April, 2017).

20. Vavlukis A, **Nestorovska AK**, Sterjev Z, Grozdanova A, Vavlukis M, et al. (2017) Influence of ABCB1 C3435T Genotype on Clinical Cardiovascular Outcomes in Coronary Artery Disease Patients on Clopidogrel Treatment. *MOJ Drug Des Develop Ther* 1(2): 00007. DOI: 10.15406/mojddt.2017.01.00007
21. Zareski R, **Kapedanovska Nestorovska A**, Grozdanova A, Dimitrova B, Suturkova LJ, Sterjev Z. The Effects of the New Methodology Application on the Method of Pricing of Drugs-The Case of the Republic of Macedonia. *Value Health Reg Issues*. 2016 Sep;10:19-28.
22. Acevski Stevche, Minov Jordan, Sterjev Zoran, Zareski Rubin, **Kapedanovska Nestorovska Aleksandra** and Suturkova Ljubica. Cost Effectiveness Analysis of Antibiotic Regimens Used in Outpatient Treatment of Exacerbation of Chronic Obstructive Pulmonary Disease (COPD). *Adv Pharmacoepidemiol Drug Saf* 2016, 5:5.
23. Aleksandra Grozdanova, Katerina Anchevska Netkovska, Zorica Naumovska, Aleksandra **Kapedanovska Nestorovska**, Zoran Sterjev, Ljubica Shuturkova. Market access of biosimilar medical products – economical, regulatory and clinical issues. *Macedonian pharmaceutical bulletin*, 62 (suppl) 41 - 42 (2016), ISSN 1409 – 8695, UDC: 615.2-027.512
24. Zoran Sterjev, Rubin Zareski, Katerina Anchevska Netkovska, Zorica Naumovska, Aleksandra **Kapedanovska Nestorovska**, Aleksandra Grozdanova, Ljubica Shuturkova. Impact of parallel trade/import of pharmaceuticals in Central East European Countries. *Macedonian pharmaceutical bulletin*, 62 (suppl) 37 - 38 (2016) ISSN 1409 – 8695, UDC: 615.2:339.562(4-11).
25. Selveta Shuleta-Qehaja, Aleksandra Grozdanova, Aleksandra, **Kapedanovska Nestorovska**, Zorica Serafimoska, Ljubica Shuturkova, Zoran Sterjev. Evaluation of reliability and validity of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) questionnaire (Albanian version) among breast cancer patients from Kosovo. *Macedonian pharmaceutical bulletin*, 62 (suppl) 59 - 60 (2016), ISSN 1409 – 8695, UDC: 618.19-006.6-052.
26. Aleksandra **Kapedanovska-Nestorovska**, Zorica Naumovska, Zoran Sterjev, Ljubica Suturkova, Aleksandra Grozdanova. The advertising influence on pharmacist recommendations and consumer selection of over-the-counter drugs. *Macedonian pharmaceutical bulletin*, 62 (suppl) 107 - 108 (2016), ISSN 1409 – 8695, UDC: 615.2:339.187(497.7).
27. Biljana Indova, Zorica Naumovska, Aleksandra **Kapedanovska Nestorovska**, Aleksandra Grozdanova, Ljubica Suturkova, Zoran Sterjev. Awareness of the importance of self-management in Macedonian diabetes patients. *Macedonian pharmaceutical bulletin*, 62 (suppl) 113 - 114 (2016), ISSN 1409 – 8695, UDC: 616.379-008.64-052-047.22(497.7)
28. Biljana Lazarova, Aleksandra **Kapedanovska Nestorovska**, Zorica Naumovska, Aleksandra Grozdanova, Ljubica Suturkova, Zoran Sterjev. Evaluation of rational / irrational drug use at orthopedic department in Clinical Hospital Stip in the period from January to April 2013. *Macedonian pharmaceutical bulletin*, 62 (suppl) 115 - 116 (2016), ISSN 1409 – 8695, UDC: 615.035.7(497.731)“2013”
29. Stefan Matik, Ana Vavlukis, Aleksandra **Kapedanovska Nestorovska**, Zorica Naumovska, Aleksandra Grozdanova, Zoran Sterjev. Antimicrobial resistance to antibacterial agents in common respiratory tract pathogens in pediatric population. *Macedonian pharmaceutical bulletin*, 62 (suppl) 637 - 638 (2016), ISSN 1409 – 8695, UDC: 615.33.015.8

30. Ana Vavlukis, Lile Zdraveska, Viktorija Nikolovska, Aleksandra **Kapedanovska**, **Nestorovska**, Zoran Sterjev, Aleksandra Grozdanova, Zorica Naumovska. Influence of ABCB1 C3435T genotype on clinical cardiovascular outcomes in coronary artery disease patients on Clopidogrel treatment. *Macedonian pharmaceutical bulletin*, 62 (suppl) 645 - 646 (2016), ISSN 1409 – 8695, UDC: 615.273.53:616.132.2, 616.132.2-085.273.53
31. Aleksandar Spirov, Aleksandra **Kapedanovska** Nestorvska, Aleksandra Grozdanova, Zoran Sterjev, Zorica Naumovska. Pharmacovigilance practice in community pharmacies. *Macedonian pharmaceutical bulletin*, 62 (suppl) 665 - 666 (2016), ISSN 1409 – 8695, UDC: 614.27.
32. Aleksandra **Kapedanovska** **Nestorovska**, Zorica Naumovska, Zoran Sterjev, Aleksandra Grozdanova, Aleksandar Dimovski, Ljubica Suturkova. The cost effectiveness of genetic testing for CYP2C19 variants to guide antiplatelet therapy with clopidogrel or prasugrel in R.Macedonia. *Int J Clin Pharm* (2016) 38: 470. doi:10.1007/s11096-015-0240-y
33. Zorica Naumoska, Aleksandra K. **Nestorovska**, Aleksandra Grozdanova, Kristina Hristova, Aleksandar Dimovski, Ljubica Suturkova, Zoran Sterjev. Trends in utilization of stains in republic of Macedonia 2013-2015. 6th Adriatic Congress of Pharmacoeconomics and Outcomes Research. Bled, Slovenia, 21-24 April, 2016. *Pharmaca* 2016; 52, (Supl. 1)
34. Grapci AD, Dimovski AJ, **Kapedanovska** A, Vavlukis M, Eftimov A, Geshkovska NM, Labachevski N, Jakjovski K, Gorani D, Kedev S, Mladenovska K . Frequencies of single-nucleotide polymorphisms and haplotypes of the SLCO1B1 gene in selected populations of the western balkans . *Balkan J Med Genet*. 2015 Dec 30;18(1):5-21.
35. Daka A, Dimovski A, **Kapedanovska** A, Vavlukis M, Eftimov A, Labachevski N, Jakjovski K, Geshkovska MN, Nebija D, Mladenovska K. Effects of single nucleotide polymorphisms and haplotypes of the SLCO1B1 gene on the pharmacokinetic profile of atorvastatin in healthy Macedonian volunteers. *Pharmazie*. 2015.
36. Nestorovska A, Naumoska Z, Grozdanova A, Stoleski D, Ivanovska A, Risteski M, Vasev N, Ismaili I, Stefanovski P, Dimovski A, Suturkova L, Sterjev Z. Subcutaneous Vs Intravenous Administration Of Trastuzumab In Her2+ Breast Cancer Patients: A Macedonian Cost-Minimization Analysis. *Value Health*. 2015 Nov;18(7):A463
37. Aleksandra **Kapedanovska** **Nestorovska**, Zorica Naumovska, Zoran Sterjev, Aleksandra Grozdanova, Aleksandar Dimovski, Ljubica Shuturkova. The cost-effectiveness of cytochrome p450 (CYP2D6 and CYP2C19) genotype screening for optimization of therapy with risperidone and clopidogrel treatment in R. Macedonia 6th Adriatic Congress of Pharmacoeconomics and Outcomes Research. Bled, Slovenia, 21-24 April, 2016. *Pharmaca* 2016; 52, (Supl. 1).
38. **Nestorovska** A, Naumoska Z, Grozdanova A, Stoleski D, Ivanovska A, Risteski M, Vasev N, Ismaili I, Stefanovski P, Dimovski A, Suturkova L, Sterjev Z. Subcutaneous Vs Intravenous Administration Of Trastuzumab In Her2+ Breast Cancer Patients: A Macedonian Cost-Minimization Analysis. *Value Health*. 2015 Nov;18(7):A463.
39. Naumovska Z, **Nestorovska** AK, Filipce A, Sterjev Z, Brezovska K, Dimovski A, Suturkova LJ. Pharmacogenetics and antipsychotic treatment response. *Pril (Makedon Akad Nauk Umet Odd Med Nauki)*. 2015;36(1):53-67. Review.
40. **Kapedanovska** **Nestorovska** A, Jakovski K, Naumovska Z, Hiljadnikova Bajro M, Sterjev Z, Eftimov A, Matevska Geskovska N, Suturkova L, Dimitrovski K, Labacevski N, Dimovski AJ. Distribution of the most Common Genetic Variants Associated with a Variable Drug Response in the Population of the Republic of Macedonia. *Balkan J Med Genet*. 2015 Apr 10;17(2):5-14.
41. Grozdanova, A. Ancevska Netkovska K, Sterjev Z, Naumovska Z, **Kapedanovska** **Nestorovska** A, Suturkova Lj. Impact of biosimilar medicinal products in the EU pharmaceutical market.. *Clinical Therapeutics* , Volume 37 , Issue 8 , e163

42. Naumovska Z, **Nestorovska** AK, Sterjev Z, Filipce A, Dimovski A, Suturkova L. Genotype variability and haplotype profile of ABCB1 (MDR1) gene polymorphisms in Macedonian population. *Pril (Makedon Akad Nauk Umet Odd Med Nauki)*. 2014;35(3):121-33.

2013-2006

43. Jakovski K, **Nestorovska** AK, Labacevski N, Dimovski AJ. Characterization of the most common CYP2C9 and CYP2C19 allelic variants in the population from the Republic of Macedonia. *Pharmazie*. 2013 Nov;68(11):893-8.
44. Sterjev Z, Kiteva G, Cvetkovska E, Petrov I, Kuzmanovski I, Ribarska T, **Nestorovska** AK, Matevska N, Trajkovic-Jolevska S, Dimovski A, Suturkova Lj. Influence of the SCN1A IVS5N + 5 G>A Polymorphism on Therapy with Carbamazepine for Epilepsy. *Balkan J Med Genet*. 2012 Jun;15(1):19-24.
45. Sterjev Z, Trencavska GK, Cvetkovska E, Petrov I, Kuzmanovski I, Ribarska JT, **Nestorovska** AK, Matevska N, Naumovska Z, Jolevska-Trajkovic S, Dimovski A, Suturkova L. The association of C3435T single-nucleotide polymorphism, Pgp-glycoprotein gene expression levels and carbamazepine maintenance dose in patients with epilepsy. *Neuropsychiatr Dis Treat*. 2012;8:191-6.
46. Z. Sterjev, G. A. Kiteva-Trencavska, J. T. Ribarska, E. Cvetkovska\_ I. Kuzmanovski, I. Petrov, A. K. **Nestorovska**, N. Matevska, Z. Naumoska, A. Dimovski, and L. Suturkova. Effects of UGT1A6\*2 genetic polymorphism on the doses, plasma concentration and metabolism of valproic acid in patient with epilepsy from R. Macedonia. *Epilepsia*, 53(Suppl. 5):1-245, 2012
47. Bajro MH, Josifovski T, Panovski M, Jankulovski N, **Nestorovska** AK, Matevska N, Petrusevska N, Dimovski AJ. Promoter length polymorphism in UGT1A1 and the risk of sporadic colorectal cancer. *Cancer Genet*. 2012 Apr;205(4):163-7.
48. Jakovski K , **Kapedanovska Nestorovska** A , Labacevski N , Dimovski AJ. Frequency of the most common CYP3A5 polymorphisms in the healthy population of the Republic of Macedonia. *Macedonian pharmaceutical bulletin*, 58 (1, 2) 25 - 30 (2012)
49. Z. Serafimoska, A. **Kapedanovska Nestorovska**, Lj. Suturkova, T.N. Johansen, K. Frydenvang, Phenylalanine derivatives, new selective ligands for AMPA and Kainate receptor subunits of ionotropic glutamate receptors. *Macedonian pharmaceutical bulletin 2011*, 56(Suppl): 336. Oral presentation
50. **Kapedanovska Nestorovska** A, Sterjev Z, Serafimoska Z, Matevska N, Josifovski T, Jankulovski N, Panovski M, Petrusevska N, Suturkova Lj, Dimovski A. J. SMAD7 rs4939827 risk variant is associated with poor outcome in colorectal cancer patients from R. Macedonia. *European Journal of Human Genetics* 2011; 19 (Suppl.2):201.
51. Sterjev Z, Kiteva G, **Kapedanovska Nestorovska** A, Matevska N, Serafimoska Z, Dimovski AJ, Suturkova L. Influence of genetic variants in EPHX1 gene on the CBZ doses in the patients from R. Macedonia. *Epilepsia* 2011, 52(Suppl. 6): 116.
52. Sterjev Z, Vlado B, **Nestorovska Kapedanovska** A, Naumoska Z, Grozdanova A, Suturkova Lj. Evaluation of patient from different aged groups about their satisfaction with pharmaceutical community services in R. Macedonia. *Macedonian pharmaceutical bulletin 2011*, 56(Suppl): 115-116.
53. **Kapedanovska Nestorovska** A, Serafimoska Z, Sterjev Z, Josifovski T, Petrusevska N, Suturkova L, Dimovski AJ. Thymidylate Synthase Enhancer Region (TSER) 2R/3R polymorphisms as an independent Risk Factor for Colorectal Cancer in Macedonian population. *Macedonian pharmaceutical bulletin 2011*, 56(Suppl): 348-349

54. Serafimoska Z, **Kapedanovska Nestorovska** A, Suturkova Lj, Tommy NJ, Frydenvang K. Phenylalanine derivatives, new selective ligands for ampa- and kainate receptor subunits of ionotropic glutamate receptors. Macedonian pharmaceutical bulletin 2011, 56(Suppl): 336.
55. **Kapedanovska Nestorovska** A, Dimitrovska Cvetkovska A, Suturkova Lj . Association between CYP2C19\*2 variant and clinical outcome in Clopidogrel treated patients from Republic of Macedonia. Makedonsko Farmaceutvski Bilten. 2011;56((1, 2)):37-44
56. Sterjev Z, Vlaco B, **Kapedanovska Nestorovska** A, Naumoska Z, Grozdanova A, Suturkova Lj. Assessment of patient satisfaction with pharmaceutical community services in R. Macedonia. Macedonian pharmaceutical bulletin 2010, 56(1,2): 23-28.
57. Serafimoska Z, **Kapedanovska Nestorovska** A, Suturkova Lj, Szymańska E, Pickering D, Frydenvang K, Johansen N T. 3-Substituted Phenylalanines, selective ligands for AMPA and Kainate receptor subunits. Rhodes 2010, 18th EuroQSAR Symposium abstract book.
58. Serafimoska Z, **Kapedanovska Nestorovska** A, Suturkova Lj, Szymańska E, Pickering D, Frydenvang K, Johansen N T. (S)-EL-7 new selective competitive antagonist for AMPA and KA receptors. Thessaloniki 2010, Hellenic Symposium of Medicinal Chemistry abstract book.
59. Sterjev Z, Kiteva G, **Nestorovska Kapedanovska** A, Matevska N, Serafimoska Z, DonevaA, Dimovski AJ, Suturkova, Lj. *SCN1A IVS5N + 5 G-A polymorphism in patients with epilepsy from R.Macedonia*, 8<sup>th</sup>European Congress on Epileptology Berlin 2010,E557,p.217.
60. Matevska N., Josifovski T., **Kapedanovska** A., Sterjev Z, Serafimoska Z, Panovski M, Jankulovski, N., Petrusavska N, Angelovska, B., Petrusavska, G., Suturkova L, Dimovski AJ, *Methylenetetrahydrofolate reductase C677T Polymorphism and risk of colorectal cancer in the Macedonian population*, Balcan Journal of Medical Genetics 2008 Vol 11(2):17-23.
61. Josifovski T., Matevska N., Hiljadnikova-Bajro M., Sterjev Z., **Kapedanovska** A., Serafimoska Z., Despotovska S., Petrusavska N., Panovski M., Suturkova L., Dimovski AJ. *Cyclin D1 G870A Variant is Associated with Increased Risk of Microsatellite Instability-Positive Colorectal Cancer in Young Male Patients*, Balcan Journal of Medical Genetics 2007 Vol 10(2):29-36
62. Sterjev Z., **Kapedanovska** A., Serafimoska Z, Josifovski T, Panovski M., Suturkova L, A.J. Dimovski. *Methylenetetrahydrofolate reductase C677T polymorphism and colorectal cancer risk in Republic of Macedonia*. International Symposium of Medicinal Chemistry Research and Development 2007.
63. Hiljadnikova-Bajro M., Josifovski T., Sterjev Z., **Kapedanovska** A., Serafimoska Z., Matevska N., Despotovska S., Petrusavska N., Panovski M., Suturkova L., Dimovski AJ., *Microsatellite Instability and Loss of Heterozygosity in colorectal cancer patients from the Republic of Macedonia*, Macedonian Pharmaceutical Bulletin 2007, 53 (1,2): 158-159
64. Hiljadnikova-Bajro M., Josifovski T., Sterjev Z., **Kapedanovska** A., Serafimoska Z., Matevska N., Despotovska S., Petrusavska N., Panovski M., Suturkova L., Dimovski AJ., *Genetic Polymorphism in UGT1A1 and risk of colorectal cancer*, Macedonian Pharmaceutical Bulletin 2007, 53 (1,2): 156-157
65. Hiljadnikova-Bajro M., Josifovski T., Sterjev Z., **Kapedanovska** A., Serafimoska Z., Matevska N., Despotovska S., Petrusavska N., Panovski M., Suturkova L., Dimovski AJ., *IGF1 gene promotor variant as risk modifier for colorectal cancer*, Macedonian Pharmaceutical Bulletin 2007, 53 (1,2): 160-161
66. Josifovski T., Hiljadnikova-Bajro M., Sterjev Z., **Kapedanovska** A., Serafimoska Z., Panovski M., Suturkova L., Dimovski A.J. *Genomic instability patterns in patients with colorectal cancer from Macedonia*, Proceedings from the 7<sup>th</sup> Balkan Meeting on Human Genetics, Balcan Journal of Medicinal Genetics (BJMG) 2006, Vol 9(3,4): 67.
67. Josifovski T., Hiljadnikova-Bajro M., Sterjev Z., **Kapedanovska** A., Serafimoska Z., Panovski M., Suturkova L., Dimovski A.J. - *Familial colorectal cancer in Macedonia*, Proceedings from the 7<sup>th</sup> Balkan Meeting on Human Genetics, BJMG 2006, Vol 9(3,4): 68.

Sterjev Z., Serafimovska Z., **Kapedanovska A.**, Hiljadnikova-Bajro M., Josifovski T., Panovski M., Soturkova L., Dimovski A.J. –*Low penetrance alleles predisposing to colorectal cancer in Macedonian patients*, Proceedings from the 7<sup>th</sup> Balkan Meeting on Human Genetics, BJMG 2006,